Elekta AB (STU:EJXB) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:EJXB Elekta AB STU:EJXB
75 GF Score
Price €4.87
GF Value €5.24
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Elekta AB Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:EJXB
75GF Score
Elekta AB STU:EJXB
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Elekta AB (STU:EJXB) Overvalued in 2026?

Based on GuruFocus' analysis, Elekta AB stock appears to be undervalued. The current stock price of €4.87 is trading 7% below its estimated GF Value™ of €5.24. GuruFocus considers Elekta AB to be Fairly Valued.

Key valuation signals for STU:EJXB:

  • Dividends Received:
  • GF Value™: €5.24 vs. price of €4.87 (7% below fair value)
  • GF Score™: 75/100 with 5 warning signs

No single metric tells the full story. See the STU:EJXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Elekta AB Business Description

Address Hagaplan 4, Box 7593, Stockholm, SWE, 11368
Sweden-based Elekta develops, manufactures, and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy. The company has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms, as well as brachytherapy installations. The company's sales are evenly distributed across geographies, with North and South America accounting for 29%; Europe, the Middle East, and Africa accounting for 37%; and the Asia-Pacific contributing the remainder.
75GF Score

Get the complete analysis for STU:EJXB

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.87
Price
€5.24
GF Value